Work

IFx-Hu2.0 phase I first in human study for unresectable melanoma for an intralesional “in-situ vaccine” approach.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e21542

Authors: Joseph Markowitz, Michael Shamblott, Andrew Scott Brohl, Amod Sarnaik, Zeynep Eroglu, Nikhil I. Khushalani, Pei-Ling Chen, Deanryan B. De-Aquino, Vernon K. Sondak, Ahmad A. Tarhini, Youngchul Kim, Shari Pilon-Thomas

Institution: Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4282027587

Cites:

Cited by: 6

Related to: 10